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LPPs (lipid phosphate phosphatases) are members of a family of
enzymes that catalyse the dephosphorylation of lipid phosphates.
The only known formof regulation of this family of enzymes is via
de novo expression of LPP isoforms in response to growth factors.
In this respect, we evaluated the effect of moderate increases in
the expression of recombinant LPP1 on signal transduction by
both G-protein-coupled receptors and receptor tyrosine kinases.
We present evidence for a novel role of LPP1 in reducing PDGF
(platelet-derived growth factor)- and lysophosphatidic acid-in-
duced migration of embryonic fibroblasts. We demonstrate that
the overexpression of LPP1 inhibits cell migration by reducing the
PDGF-induced activation of p42/p44 MAPK (mitogen-activated
protein kinase). This appears to occur via a mechanism that in-
volves the LPP1-induced down-regulation of typical PKC (protein
kinase C) isoform(s), which are normally required for PDGF-in-
duced activation of p42/p44 MAPK and migration. In this regard,
DAG (diacylglycerol) levels are high and sustained in cells over-
expressing LPP1, suggesting a dynamic interconversion of
phosphatidic acid into DAG by LPP1. This may account for the
effects of LPP1 on cell migration, as sustained DAG is known to
down-regulate PKC isoforms in cells. Therefore the physiological
changes in the expression levels of LPP1might represent a hetero-
logous desensitization mechanism for attenuating PKC-mediated
signalling and regulation of cell migration.
Keywords: cellmigration, lipid phosphate phosphatase, lysophos-
phatidic acid, p42/p44mitogen-activated protein kinase (MAPK),
phosphatidic acid, platelet-derived growth factor.
INTRODUCTION
LPPs (lipid phosphate phosphatases) are integral membrane pro-
teins that display broad substrate specificity in vitro, catalysing the
dephosphorylation of lipid phosphates [e.g. S1P (sphingosine 1-
phosphate), LPA (lysophosphatidic acid), PA (phosphatidic acid)
and C1P (ceramide 1-phosphate)] in a Mg2+-independent and N-
ethylmaleimide-insensitive manner [1]. Three mammalian LPP
isoforms have been cloned, termed LPP1, LPP2 and LPP3 [2–6].
LPP3 corresponds to the endoplasmic reticulum protein, Dri42,
which is up-regulated during differentiation of intestinal epithelial
cells [7]. Recently, LPP has been suggested to belong to a family of
lipid phosphatases/phosphotransferases that also includes plasti-
city-related genes 1–4 and sphingomyelin synthases [8]. LPP is
predicted to have six transmembrane domains, with the active site
facing the extracellular side of the plasma membrane or the lu-
minal side of intracellular membranes [9]. The presence of LPP1,
LPP2 and LPP3 at the plasma membrane has been detected with
isoform-selective antibodies [2,10–13] and epitope-tag antibodies
[13–16]. LPP1 and LPP3 have also been identified in caveolae
[11,12], whereas LPP2 and LPP3 are present in cytoplasmic vesi-
cles in CHO (Chinese hamster ovary) cells [13]. LPP2 and LPP3
are constitutively co-localized with SK1 (sphingosine kinase 1),
and LPP3/SK1 is recruited to a perinuclear compartment upon
induction of PLD1 (phospholipase D1) in CHO cells [13].
LPPs have the potential to influence physiological processes
that are regulated by the GPCR (G-protein-coupled receptor) ago-
nists S1P and LPA. This may involve dephosphorylation of extra-
cellular S1P andLPAvia an ecto-LPP activity,whichmay limit the
bioavailability of these agonists at their respective GPCRs, S1P1–
S1P5 and LPA1–LPA3 [4,14–16]. Recent studies have shown that
the overexpression of LPP1 reduces both acute and chronic LPA-
stimulated responses, including activation of p42/p44MAPK (mi-
togen-activated protein kinase), PLD, DNA synthesis and cell
division, while having no effect on LPA receptor function or ex-
pression [10,13,17]. Similarly, overexpression of LPP3 in ovarian
cancer cells decreases colony formation and reduces tumour
growth in vitro and in vivo [18]. In addition, overexpression of
LPP2 or LPP3 reduces the S1P- and LPA-stimulated activation
of p42/p44 MAPK in serum-deprived HEK-293 cells [10,13].
This effect is blocked by pre-treating HEK-293 cells with the
caspase-3/7 inhibitor, Ac-DEVD-CHO (N-acetyl-Asp-Glu-Val-
Asp-aldehyde) [13]. Therefore LPP2 and LPP3 appear to regulate
the apoptotic status of serum-deprived HEK-293 cells. In this
regard, LPP2 reduced basal intracellular PA levels, whereas
LPP3 reduced intracellular S1P in serum-deprived HEK-293 cells
[13]. These data are consistent with an important role for LPP2
and LPP3 in regulating an intracellular pool of PA and S1P
respectively, which may govern apoptosis in response to cellular
stress.
To date, there is no evidence that LPP isoforms are acutely
regulated (e.g. phosphorylation) by extracellular stimuli. How-
ever, growth factors [e.g. EGF (epidermal growth factor)] and
androgens have been shown to increase de novo expression of
endogenous LPP3 protein and endogenous LPP1 mRNA trans-
cript respectively [3,19]. In the present study, we have evaluated
the functional consequences of increased LPP1 expression on
signal transduction by both GPCRs and RTKs (receptor tyrosine
kinases) in mammalian cells. This was achieved by comparing
the ability of PDGF (platelet-derived growth factor), a growth
Abbreviations used: CHO, Chinese hamster ovary; DAG, diacylglycerol; DAPI, 4,6-diamidino-2-phenylindole; DMS, N,N-dimethylsphingosine; EGF,
epidermal growth factor; FCS, foetal calf serum; GPCR, G-protein-coupled receptor; LPA, lysophosphatidic acid; LPP, lipid phosphate phosphatase;
MAPK, mitogen-activated protein kinase; MEF, mouse embryonic fibroblast; PA, phosphatidic acid; PDGF, platelet-derived growth factor; PKC, protein
kinase C; PLD, phospholipase D; RTK, receptor tyrosine kinase; S1P, sphingosine 1-phosphate; SK1, sphingosine kinase 1.
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Figure 1 Functional role of LPP1 in regulating p42/p44 MAPK signalling in HEK-293 cells
Stable vector- and LPP1-transfected HEK-293 cells were transiently transfected with or without a plasmid construct encoding the PDGFβ receptor. The cells were treated with or without 5 µM S1P,
5 µM LPA, 30 units/ml thrombin (Thr) or 10 ng/ml PDGF for 10 min. Lysates were Western-blotted using anti-phospho-p42/p44 MAPK antibody. The Western blot shows that the ligand-induced
activation of p42/p44 MAPK is reduced in HEK-293 cells that stably overexpress LPP1. Blots were stripped and re-probed with anti-p42 MAPK antibody (to confirm equal protein loading). ‘V’
represents cells that are stably transfected with vector.
factor that binds to a PDGFβ RTK, and a GPCR agonist, LPA, to
stimulate migration of embryonic fibroblasts isolated from wild-
type and LPP1 transgenic mice.
MATERIALS AND METHODS
Materials
All biochemicals including PDGF, LPA and FITC-conjugated
secondary antibody were from Sigma Chemical Co. Cell culture
supplies were from Invitrogen (Paisley, U.K.). Anti-phospho-p42/
p44 MAPK (polyclonal) and anti-p42 MAPK antibodies were
from New England Biolabs. Anti-PKC (protein kinase C)
(recognizes α, β and γ ) antibody was from Upstate Ltd. S1P
was from Avanti. PDGFβ receptor plasmid construct was kindly
given by Professor C.-H. Heldin (Ludwig Institute for Cancer
Research, Uppsala, Sweden).
Cell culture
MEFs (mouse embryonic fibroblasts) derived from either wild-
type or LPP1 transgenic mice [20] were maintained in Dulbecco’s
modified Eagle’s medium containing 10% (v/v) FCS (foetal calf
serum) and penicillin/streptomycin. HEK-293 cells that stably
overexpress LPP1 [10] were maintained in minimum essential
medium supplemented with FCS (10%, v/v) and penicillin/
streptomycin. Cells were deprived of serum for 24 h before
stimulation with agonist.
Transfection
Cells were transiently transfected with plasmid constructs as re-
quired. Cells at 75–95% confluence were placed in medium con-
taining 1% FCS and transfected with 1 µg of plasmid construct
following complex formation with LipofectAMINETM 2000, ac-
cording to the manufacturer’s instructions. The cDNA-containing
medium was removed after incubation for 24 h at 37 ◦C, and
the cells were incubated for a further 18 h before agonist addi-
tions.
SDS/PAGE and Western blotting
Cell lysates were prepared using sample buffer containing 62 mM
Tris/HCl, pH 6.7, 1.25% (w/v) SDS, 10% (v/v) glycerol, 3.75%
(v/v) mercaptoethanol and 0.05% (w/v) Bromophenol Blue,
and proteins were resolved by SDS/PAGE. Western blotting
with specific antibodies was used to identify proteins of interest
[10]. Immunoreactive proteins were visualized using enhanced
chemiluminescence detection.
Immunofluorescence
Cells were grown on 12 mm glass coverslips to 60–90% conflu-
ence, and transfected as described above. Cells were fixed in
3.7% formaldehyde in PBS for 10 min, and then permeabilized
in 0.1% (v/v) Triton X-100 in PBS for 1 min. Non-specific
binding was reduced by pre-incubating cells in blocking solution
containing 5% FCS/1% BSA in PBS for 1 h. Cells were incu-
bated with primary antibodies (1:100 dilution of antibody in
blocking solution) for 1 h at room temperature (or overnight
at 4 ◦C), and then incubated with FITC-conjugated secondary
antibody (1:100) for 1 h. Cells were mounted on glass slides using
Vectashieldmountingmedium, and visualized using aNikonE600
epifluorescence microscope.
LPP activity
A 100000 g membrane pellet was combined with a reaction
mixture consisting of 50 µM [32P]PA (0.01 µCi/reaction), 8 mM
Triton X-100, 100 mM Tris/maleate, pH 6.5, and 1 mM rac-
glycerophosphate in 100 µl. After a 10 min incubation at 30 ◦C,
4 ml of 0.1 M phosphoric acid, 296 µl of water and 400 µl of
1 M HClO4 were added, and the unreacted substrate was ex-
tracted twice with water-saturated butan-1-ol. To a 500 µl aliquot
of the reaction mixture, 50 µl of 125 mM ammonium molybdate
was added, and the phosphomolybdate complex was extracted
with 600 µl of 2-methyl-1-propanol/benzene (1:1, v/v). The
radioactivity of the upper phase was measured by scintillation
counting.
Cell migration
MEFs were grown to 90–95% confluence and were quiesced by
serum starvation. The cell monolayer was wounded by a scratch
using a 1 ml pipette tip. The wounded monolayer was then
treated without or with agonist for 8 h, after which time the cells
were stained with DAPI (4,6-diamidino-2-phenylindole) and the
area of cell-free wound was digitally photographed. The wound
healing effect is presented as the number of cells migrating into
the wounded area within a standard field of view (×40 mag-
nification).
RESULTS AND DISCUSSION
LPP1 functions to regulate p42/p44 MAPK activation
in HEK-293 cells
We have used two cell model systems to evaluate the functional
consequences of the overexpression of LPP1. First, we have used
c© 2006 Biochemical Society
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Figure 2 LPP1 reduces PDGF-induced activation of p42/p44 MAPK in LPP1 transgenic MEFs
MEFs from wild-type (WT) and LPP1 transgenic mice were stimulated with or without PDGF (10 ng/ml) or S1P (5 µM) or LPA (5 µM) for 10 min. (A) The Western blot shows that the PDGF- and
S1P-induced activation of p42/p44 MAPK is reduced in MEFs from LPP1 transgenic mice (with 2, 8 or 20 gene copies) compared with MEFs from wild-type mice; (B) immunofluorescent cell imaging
with anti-phospho-p42/p44 MAPK antibody/FITC-conjugated secondary antibody and DAPI. (C) The Western blot shows that the LPA-induced activation of p42/p44 MAPK is reduced in MEFs from
LPP1 transgenic mice compared with MEFs from wild-type mice. (D and E) Wild-type MEFs were transfected with plasmid constructs encoding (D) Myc-tagged wild-type SK1 or dominant-negative
SK1 (DNSK1) or (E) Myc-tagged wild-type SK2 or dominant-negative SK2 (DNSK2). The Western blot shows that neither wild-type nor dominant-negative sphingosine kinase isoforms has an effect
on p42/p44 MAPK activation. Also included in (D) and (E) (top panels) are Western blots probed with anti-Myc-tag antibody, showing overexpression of SK1/DNSK1 or SK2/DNSK2. (F) MEFs
from wild-type mice were pre-treated with or without DMS (0.001–10 µM) for 10 min prior to stimulation with agonist. The Western blots (left) show the lack of effect of DMS on PDGF- or S1P-
or LPA-induced p42/p44 MAPK activation. Also shown is the lack of effect of DMS on PDGF-induced cell migration in the scratch wound healing assay (upper right). The histogram (below) shows
quantitative data for the cell migration assay performed in three or four determinations from a representative experiment (*P < 0.01 compared with vehicle control).
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Figure 3 LPP1 reduces LPA- and PDGF-induced migration of MEFs
In the scratch wound healing assay, MEFs from wild-type and LPP1 transgenic mice were stimulated with PDGF (10 ng/ml) or S1P (5 µM) or LPA (5 µM) for 8 h. The photographs show: (A) the
inhibitory effect of LPP1 (MEFs from LPP1 transgenic mice) on LPA-induced cell migration [*P < 0.01 compared with control; **P < 0.01 compared with LPA response in wild-type (wt) MEFs];
and (B) the inhibitory effect of PD098059 (10 µM for 30 min) and the LPP1 transgene on PDGF-induced cell migration (*P < 0.01 compared with the control; **P < 0.01 compared with the PDGF
response in the absence of PD098059). The Western blot confirms the inhibitory effect of PD098059 on the PDGF-induced activation of p42/p44 MAPK (10 min) in MEFs from wild-type mice. The
histograms show quantitative data for the cell migration assay performed in three or four determinations from a representative experiment.
HEK-293 cells that have been stably transfected with a plasmid
construct encoding LPP1. This results in an approx. 60–70-fold
increase in LPP1 activity using dioleoyl-PA as a substrate [10].
We have previously shown that S1P and LPA stimulate activation
of p42/p44 MAPK in HEK-293 cells [10]. This is mediated
by lipid-phosphate GPCR, evident from data showing that the
cellular responses to S1P or LPA are blocked by pertussis toxin,
which functions to uncouple Gi from LPA and S1P receptors [10].
Overexpression of LPP1 in HEK-293 cells reduced the activation
of p42/p44 MAPK by S1P, LPA and thrombin (Figure 1). How-
ever, a major focus here was to investigate whether LPP1 has an
extended repertoire of functions in terms of being able to attenu-
ate signalling by agents that use RTK. We therefore focused on
PDGF, which binds to PDGF receptors to induce a cell response.
In order to assess effects on PDGF signalling, HEK-293 cells were
transfected with plasmid construct encoding the PDGFβ receptor.
PDGF-induced responses in HEK-293 cells require ectopic
expression of the PDGFβ receptor [21]. Our findings demonstrate
that LPP1 overexpressionmarkedly reducedPDGF-induced activ-
ation of p42/p44 MAPK (Figure 1). The effects of LPP1 are
therefore heterologous in nature and are not restricted to one re-
ceptor type, and LPP1 can significantly modulate both GPCR-
and RTK-mediated signalling. The activation of p42/p44 MAPK
by PDGF in HEK-293 cells does not involve the synthesis of
intracellular S1P that is subsequently released to act as an auto-
crine signal on S1P receptors [21]. This is based on data showing
that the activation of this kinase pathway was not reduced by
pre-treating cells with D,L-threo-dihydrosphingosine, an inhibitor
of SK responsible for the synthesis of S1P [21]. Therefore an
intracellular function for LPP1 is suggested by its ability to disrupt
PDGFβ receptor signalling.
LPP1 functions to regulate p42/p44 MAPK activation in MEFs
The second approach to evaluate the functional consequence of
increasing the expression of LPP1 on GPCR- and RTK-mediated
signal transduction utilized MEFs from LPP1 transgenic mice. In
this case, we have specifically addressed the question of the role
of LPP1 in regulating endogenous PDGF receptor and LPA/S1P
receptor signal transmission. MEFs derived from colonies of
mice with different numbers of copies of the LPP1 gene {2, 8
and 20 times greater (2×, 8× and 20×) than that of wild-type
c© 2006 Biochemical Society
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mice; [20]} were used. The LPP activity increase was dependent
on gene dosage, with an approx. 3.32-fold increase in LPP
activity in the 20× compared with wild-type mice [LPP activity:
control, 12.5+
−
1.54 nmol/min per mg of protein; 8×, 30.48+
−
3.9 nmol/min per mg of protein; 20×, 41.47+
−
6.9 nmol/min per
mg of protein; n= 3–5 (means+
−
S.E.M.) using 50 µM PA as
substrate]. The increase in LPP activity is similar to the 3-fold
stimulation of LPP activity as a consequence of de-novo synthesis
of the enzyme in response to EGF [3], and is therefore comparable
with physiological changes in LPP regulation in vivo.
The stimulation of p42/p44 MAPK by PDGF, S1P or LPA
was reduced in the LPP1-overexpressing MEFs (Figures 2A–2C).
Others have reported that PDGF stimulates the release of S1P
from the MEFs [22], which acts in an autocrine manner to stimu-
late cell responses. We therefore considered the possibility that
LPP1 might also exert its effects on PDGF receptor signalling
by dephosphorylation of released S1P. However, we excluded the
possible role for autocrine S1P in the PDGF-induced activation
of p42/p44 MAPK and migration. This was evident from results
showing that overexpression of Myc-tagged wild-type or domi-
nant-negative SK1 (G81D) or SK2 (G213D) had no effect on the
PDGF- or lipid phosphate-induced activation of p42/p44 MAPK
in these cells (Figures 2D and 2E). In addition, the pre-treatment
of cells with the SK inhibitor DMS (N,N-dimethylsphingosine)
had no effect on the PDGF-, S1P- or LPA-induced activation of
p42/p44 MAPK (Figure 2F). We have also used scratch injury
of MEF monolayers to assess the effect of DMS on cell migra-
tion. Migration of wild-type MEFs in response to PDGF was evi-
denced by the appearance of cells in the scratch injury area. How-
ever, DMS was without effect on PDGF-induced cell migration
(Figure 2F) at concentrations that inhibit SK [23].
LPP1 functions to regulate PDGF-stimulated cell migration
The ability of LPA or PDGF to induce migration was significantly
reduced in MEFs from LPP1 transgenic mice (Figures 3A and
3B). S1P did not significantly stimulate cell migration of wild-
type MEFs (Figure 3A), despite activating the p42/p44 MAPK
pathway. A possible explanation for the ineffectiveness of S1P
in wild-type MEFs is that this lysolipid can bind to both stimu-
latory (S1P1) and inhibitory (S1P2) receptors that mediate migra-
tion in these cells [22,24], leading to no net effect on the
migration of MEFs. The migratory response to PDGF is depen-
dent on the activation of p42/p44 MAPK, as evidenced by re-
sults showing that pre-treatment of cells with the inhibitor of
MEK-1 (MAPK/extracellular-signal-regulated kinase kinase 1)
activation, PD098059, markedly reduced PDGF-stimulated
migration (Figure 3B). Therefore the action of LPP1 on PDGF
responses can be explained by its ability to reduce the activation
of p42/p44 MAPK in response to PDGF, which is required for
PDGF-induced cell migration.
Role of PKC signalling
DAG (diacylglycerol) levels are high and sustained in HEK-
293 cells stably expressing LPP1, and in MEFs from the LPP1
transgenic mice [10,20]. These findings support the notion that
there is dynamic interconversion of PA into DAG in cells
overexpressing LPP1. PA levels are not significantly altered. Thus
the steady-state concentration of PA may be robustly ‘buffered’,
by, for example, PLD and DAG kinase routes.
We hypothesized that the increase in DAG levels might affect
signalling pathways that are specifically regulated by PKC, as
sustained increases in DAG can induce down-regulation of PKC
isoforms that use DAG as a co-activator with calcium. Therefore
Figure 4 Role of PKC in PDGF-induced cell migration
Wild-type MEFs were pre-treated with and without Ro318220 (10µM) for 10 min and then
stimulated with (A) PDGF (10 ng/ml) or S1P (5 µM) for 10 min for p44/p42 MAPK assays, or
(B) PDGF (10 ng/ml) for 8 h for the scratch wound healing assay. (A) The Western blot shows
the inhibitory effect of Ro318220 on the PDGF- or S1P-induced activation of p42/p44 MAPK
in MEFs from wild-type mice; (B) inhibitory effect of Ro318220 on PDGF-induced migration
of wild-type MEFs in the scratch wound healing assay. The histogram shows quantitative data
for the cell migration assay performed in three or four determinations from a representative
experiment (*P < 0.01 compared with the PDGF response).
we investigated whether PKC might be involved in the PDGF-
induced regulation of p42/p44 MAPK and cell migration, and
whether the inhibitory effect of LPP1 on p42/p44 MAPK and mi-
gration is related to disruption of PKC signalling. This possi-
bility is supported by recent studies by Campbell and
Trimble [25]. These authors have shown that PKCβII is
required for PDGF-induced p42/p44 MAPK activation and mi-
gration of vascular smooth muscle cells. Moreover, Yamamura
et al. [26] have shown that down-regulation of PKCα inhibits
the migration of endothelial cells. We first evaluated the effect
of a PKC inhibitor, Ro318220, on p42/p44 MAPK activation
and cell migration. The pre-treatment of wild-type MEFs
with Ro318220 reduced PDGF- or S1P-induced activation of
p42/p44 MAPK (Figure 4A) and inhibited PDGF-induced cell
migration (Figure 4B). These findings suggest that PDGF-
stimulated p42/p44 MAPK activation and cell migration are,
indeed, PKC-dependent. Moreover, we observed that typical PKC
c© 2006 Biochemical Society
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Figure 5 Comparison of typical PKC isoform expression in wild-type
compared with LPP1 transgenic MEFs
Wild-type (WT) and LPP1 transgenic MEF lysates were subjected to Western blotting
with anti-PKC antibody. The Western blot shows that typical PKC isoform(s) are markedly
down-regulated in LPP1 transgenic MEFs.
(Mr = 80000) isoform(s) expression levels were down-regulated
in MEFs from LPP1 transgenic mice (Figure 5). Therefore the
LPP1-dependent down-regulation of PKC may account for its
ability to reduce both PDGF- and S1P-induced activation of
p42/p44 MAPK, and PDGF-stimulated cell migration.
Conclusion
We have shown here that LPP1 overexpression reduced the
PDGF- and LPA-induced migration of MEFs derived from LPP1
transgenic mice. This is the first evidence to demonstrate that
LPP1 overexpression reduces PDGFβ receptor signal transmis-
sion and response in mammalian cells. In addition, we suggest
that typical PKC isoform(s) are markedly down-regulated in
MEFs from LPP1 transgenic mice, and that this might account
for the inhibitory effect of LPP1 on PDGF- or LPA-induced
cell migration. The implication of these findings is that the re-
ported increase in LPP expression evoked by growth factors
might represent a heterologous desensitization mechanism that
attenuates cell migratory responses that require a functional PKC
signalling pathway.
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